Catalyst Biosciences, Inc. (CBIO) Company Profile
Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.
News about CBIO
2 Biotech Stocks That Tanked This Week: Can They Recover?
If you're looking for biotech stock bargains, the scrap heap isn't a bad place to start. Hardly a day goes by without a biotech meltdown somewhere, and clinical trial mishaps led to market clubbings for Anika Therapeutics (NASDAQ:ANIK) and Catalyst ...Read More>>>
Better Buy: Illumina, Inc. vs. Pacific Biosciences of California
Gene sequencing is hot these days. All you have to do to confirm it is to look at the stock performance of two of the leading makers of gene-sequencing systems. Illumina (NASDAQ:ILMN) stock is up more than 30% so far in 2018. Pacific Biosciences of C...Read More>>>
Catalyst Biosciences (CBIO) Stock Price Up -2.7%
Catalyst Biosciences Inc (NASDAQ:CBIO) rose 2.7% on Wednesday . The stock traded as high as $10.75 and last traded at $10.54. Approximately 41,790 shares traded hands during trading, a decline of 93% from the average daily volume of 568,965 shares. T...Read More>>>
Why Biogen, Baytex Energy, and Catalyst Biosciences Slumped Today
Wall Street continued its downward streak on Monday, with the Dow Jones Industrial Average falling more than 100 points. Most major benchmarks fell more modestly, with a few actually poking into positive territory on the day. Trade-sensitive stocks w...Read More>>>
Is This Why Pacific Biosciences of California Surged This Week?
What happened Shares of Pacific Biosciences of California (NASDAQ:PACB), a genetic-sequencing system manufacturer, rose 11% on Thursday and continued their climb into Friday's session. Investors appear pleased with new productivity-boosting tools t...Read More>>>